[1]冯士航,王晶,靳宏光.中医药干预PCI术后抗血小板药物低反应性研究进展[J].陕西中医,2026,(8):1149-1152，封3.[doi:DOI:10.3969/j.issn.1000-7369.2026.08.025]
　FENG Shihang,WANG Jing,JIN Hongguang.Research progress on traditional Chinese medicine interventions for antiplatelet drug hyporesponsiveness after PCI[J].,2026,(8):1149-1152，封3.[doi:DOI:10.3969/j.issn.1000-7369.2026.08.025]
点击复制

中医药干预PCI术后抗血小板药物低反应性研究进展

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年8期
页码:
1149-1152，封3
栏目:
综述
出版日期:
2026-08-05

文章信息/Info

Title:
Research progress on traditional Chinese medicine interventions for antiplatelet drug hyporesponsiveness after PCI
作者:
冯士航1; 王晶1; 靳宏光2
（1.长春中医药大学，吉林 长春 130117；2.长春中医药大学附属医院，吉林 长春 130021）
Author(s):
FENG Shihang1; WANG Jing1; JIN Hongguang2
(1.Changchun University of Chinese Medicine,Changchun 130117,China；2.Affiliated Hospital of Changchun University of Chinese Medicine,Changchun 130021，China)
关键词:
经皮冠状动脉介入治疗; 中医药; 抗血小板药物低反应性; 高血小板反应性; 氯吡格雷抵抗; 阿司匹林抵抗; 血小板聚集
Keywords:
Percutaneous coronary intervention; Traditional Chinese medicine; Antiplatelet drug hyporesponsiveness; High platelet reactivity; Clopidogrel resistance; Aspirin resistance; Platelet aggregation
分类号:
R 541.4
DOI:
DOI:10.3969/j.issn.1000-7369.2026.08.025
文献标志码:
A
摘要:
经皮冠状动脉介入治疗（PCI）术后，患者可出现抗血小板药物低反应性，表现为高血小板反应性，阿司匹林抵抗和氯吡格雷抵抗是较常被研究的具体类型。高血小板反应性与支架内血栓形成及缺血性事件风险增加密切相关。尽管基因检测及个体化用药策略在一定程度上改善了抗血小板治疗效果，但降低缺血风险的同时会增加出血风险，是当前临床面临的主要挑战之一。中医药在改善PCI术后抗血小板药物低反应性方面逐渐受到关注。中医药在一定程度上能够降低血小板反应性，对炎症反应及血管内皮功能具有调节作用。系统梳理中医药改善PCI术后抗血小板药物低反应性研究进展，有助于解释潜在作用机制及临床应用价值，为后续优化PCI术后抗血小板治疗策略提供参考。
Abstract:
After percutaneous coronary intervention (PCI),patients may develop low responsiveness to antiplatelet drugs,characterized by high platelet reactivity.Aspirin resistance and clopidogrel resistance were two commonly studied specific types.High platelet reactivity was closely associated with an increased risk of stent thrombosis and ischemic events.Although genetic testing and individualized medication strategies had improved efficacy of antiplatelet therapy to some extent,reducing ischemic risk often increases bleeding risk,which remains one of the major clinical challenges today.Traditional Chinese medicine (TCM) had gradually gained attention for its potential in improving low antiplatelet drug responsiveness after PCI.TCM could moderately reduce platelet reactivity and modulate inflammatory responses and vascular endothelial function.A systematic review of research progress on TCM’s role in improving antiplatelet drug responsiveness post-PCI will help clarify its underlying mechanisms and clinical value,providing valuable insights for optimizing future antiplatelet treatment strategies following PCI.

参考文献/References:

[1]中华医学会心血管病学分会介入心脏病学组,中国康复医学会心脏介入治疗与康复专业委员会,国家心血管病中心专家委员会.经皮冠状动脉介入治疗患者术后长期管理中国专家共识[J].中国循环杂志,2026,41(1)：1-21.
[2]URBAN L,INGRID S,ZOLKOV J,et al.High on-treatment platelet reactivity in patients undergoing complex percutaneous coronary interventions[J].Clin Appl Thromb Hemost,2023,29：10760296231199089.
[3]STONE G W,WITZENBICHLER B,WEISZ G,et al.Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES)：A prospective multicentre registry study[J].The Lancet,2013,382(9892)：614-623.
[4]PEREIRA N L,RIHAL C S,SOD Y F,et al.Clopidogrel pharmacogenetics[J].Circ Cardiovasc Interv,2019,12(4)：e7811.
[5]PARKERW A E,STOREY R F.The role of platelet P2Y(12) receptors in inflammation[J].Br J Pharmacol,2024,181(4)：515-531.
[6]张李刚,段蓉,李正翔.不同疾病状态及联合用药对氯吡格雷抵抗的相关因素研究进展[J].中国医院用药评价与分析,2020,20(2)：249-251,256.
[7]PRADHAN A,BHANDARI M,VISHWAKARMA P,et al.Clopidogrel resistance and its relevance：Current concepts[J].J Family Med Prim Care,2024,13(6)：2187-2199.
[8]卢聪,程标.血小板功能检测在经皮冠状动脉介入术后抗血小板治疗中的应用进展[J].实用医院临床杂志,2021,18(3)：207-211.
[9]GALLI M,FRANCHI F,ROLLINI F,et al.Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention[J].Trends Cardiovasc Med,2023,33(3)：133-138.
[10]MOHAMMED S,ALI Z,MOHAMMED N,et al.Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy：Systemic review and meta-analysis[J].Frontiers in Pharmacology,2025,16：1621327.
[11]ANGIOLILLO D J,GALLI M,ALEXOPOULOS D,et al.International consensus statement on platelet function and genetic testing in percutaneous coronary intervention：2024 update[J].JACC Cardiovasc Interv,2024,17(22)：2639-2663.
[12]GALLI M,OCCHIPINTI G,BENENATI S,et al.Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles：A network meta-analysis[J].Eur Heart J Cardiovasc Pharmacother,2024,10(6)：526-536.
[13]王敏,裴蕊慧,向宗兴.CYP2C19基因型检测对急性心肌梗死经皮冠状动脉介入术后抗血小板药物治疗的临床研究[J].陕西医学杂志,2024,53(10)：1402-1406.
[14]中国医师协会心血管内科医师分会.泛血管疾病抗栓治疗中国专家共识(2024版)[J].中华医学杂志,2024,104(12)：906-923.
[15]KUNO T,WATANABE A,SHOJI S,et al.Short-term DAPT and DAPT De-escalation strategies for patients with acute coronary syndromes：A systematic review and network Meta-analysis[J].Circ Cardiovasc Interv,2023,16(9)：e13242.
[16]渊潭,李今朝.老年冠心病患者经皮冠状动脉介入术术后应用低剂量替格瑞洛的可行性及安全性研究[J].陕西医学杂志,2021,50(1)：86-88.
[17]LIN Y,JIAO K,LIU B,et al.Antiplatelet and myocardial protective effect of Shexiang Tongxin dropping pill in patients undergoing percutaneous coronary intervention：A randomized controlled trial[J].J Integr Med,2022,20(2)：126-134.
[18]田晶,徐柏榕,邢作英,等.活血化瘀中药治疗氯吡格雷抵抗有效性及安全性的Meta分析[J].中药新药与临床药理,2023,34(8)：1141-1150.
[19]潘永跃,汪丽芳,童凤军,等.冠心宁片联合氯吡格雷对冠状动脉粥样硬化性心脏病介入治疗术后患者的疗效[J].药学进展,2025,49(12)：1129-1133.
[20]李晓丽,浦强,吕军.软肝降脂胶囊对急性冠脉综合征患者血管内皮功能及血小板功能的影响[J].湖南师范大学学报(医学版),2023,20(6)：73-78.
[21]郭玉凡,付征.加味小陷胸汤联合冠状动脉支架植入术对不稳定型心绞痛病人心功能、血小板活化功能的影响[J].中西医结合心脑血管病杂志,2024,22(17)：3172-3175.〖FL)〗
〖HT〗〖FL(K2〗
[22]于乐,陈韦,齐静,等.化瘀祛痰颗粒对痰浊血瘀型急性冠脉综合征经皮冠状动脉介入治疗术后患者血小板功能及预后的影响[J].河北中医,2020,42(11)：1637-1640.
[23]曾庆萍.化瘀祛痰颗粒干预ACS患者PCI术后血小板功能及临床疗效观察[D].沈阳：辽宁中医药大学,2020.
[24]张立晶.PCI术后氯吡格雷抵抗人群证候特点及血府逐瘀胶囊干预的临床评价[D].北京：中国中医科学院,2016.
[25]陈铁军,朱修乐,沈智杰,等.新加丹参饮干预冠心病患者经皮冠状动脉介入治疗术后氯吡格雷抵抗30例[J].环球中医药,2018,11(10)：1607-1610.
[26]ZHENG S,GUO J,WANG Q.Exploring the complementary role of traditional chinese medicine in enhancing percutaneous coronary intervention outcomes：Mechanisms benefits and future research directions[J].Ther Clin Risk Manag,2025,21：1069-1083.
[27]王恒,李继忠,魏鸾颍,等.急性ST段抬高型心肌梗死患者PCI术后炎症反应特征与血管内皮功能及MACE的关系[J].临床心血管病杂志,2025,41(10)：780-786.
[28]何柱辉.冠心Ⅲ号对NSTE-ACS患者疗效及TM、TAT影响观察[D].广州：广州中医药大学,2024.
[29]孙丹.化痰活血解毒方对ACS患者PCI术后凝血机制及近期心功能的影响[D].郑州：河南中医药大学,2016.
[30]王画.抗血栓方对急性冠脉综合征PCI术后气虚血瘀证患者血管内皮功能及炎症因子的影响[D].昆明：云南中医药大学,2023.
[31]盛志伟.芪参益气滴丸治疗急性冠脉综合征PCI术后血瘀证患者的临床疗效观察[D].南京：南京中医药大学,2017.
[32]YU L,HUANG P,WANG M,et al.Comprehensive effect of Naoxintong capsule combined with western medicine on coronary heart disease after percutaneous coronary intervention：A meta-analysis[J].Front Pharmacol,2024,15：1274000.
[33]CATTANEO M.P2Y12 receptors：Structure and function[J].J Thromb Haemost,2015,13（1）：s10-s16.
[34]丁彧涵.芪黄逐瘀方调控PI3K/Akt信号通路抑制血小板活化缓解冠脉微栓塞的机制研究[D].南京：南京中医药大学,2024.
[35]王铭铭.益气活血中药配伍联合双抗抗血小板的作用与机制研究[D].北京：中国中医科学院,2016.
[36]LI J,YUAN D,JIANG L,et al.Similar inflammatory biomarkers reflect different platelet reactivity in percutaneous coronary intervention patients treated with clopidogrel：A Large-sample study from China[J].Front Cardiovasc Med,2021,8：736466.
[37]SIASOS G,OIKONOMOU E,ZAROMITIDOU M,et al.Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy[J].Atherosclerosis,2015,242(1)：102-108.
[38]田天玮,梁君昭.名中医梁君昭基于气机理论治疗冠脉支架术后心绞痛经验[J].陕西中医,2022,43(7)：939-942.

相似文献/References:

[1]白月琴,刘宇,赵晓珍,等.基于微环境认识中医药抗肿瘤转移的机制[J].陕西中医,2016,(10):1438.
[2]孙婷婷,魏 哲,郑书敏,等.自主神经调控房颤的作用机制及中医药治疗研究进展*[J].陕西中医,2019,(1):135.
　SUN Tingting,WEI zhe,Zheng Shumir,et al.The machanism of regulateion of autonomic nervous system in atrial fibrillation and the research progress about The traditional Chinese medicine[J].,2019,(8):135.
[3]膝骨性关节炎中医治疗现状研究.膝骨性关节炎中医治疗现状研究[J].陕西中医,2019,(4):543.
　WU Yongbiao,SHI Xiaobing..Current status of traditional Chinese medicine treatment for knee osteoarthritis[J].,2019,(8):543.
[4]贺建涛,胡宇才,刘 磊.活血通络散治疗冠心病PCI术后心绞痛疗效研究*[J].陕西中医,2019,(7):854.
　HE Jiantao,HU Yucai,LIU Lei..Efficacy observation of Huoxue Tongluo powder in the treatment of angina pectoris after coronary heart disease PCI[J].,2019,(8):854.
[5]祁向争,马志豪,李志强.中医药改善胃癌前病变炎症因子研究进展*[J].陕西中医,2019,(7):976.
[6]杭远远,金毓莉△.中医药在体外受精胚胎移植中的应用及机制研究概述*[J].陕西中医,2019,(11):1649.
　HANG Yuanyuan,JIN Yuli..Overview of the application and mechanism research of traditional Chinese medicine in IVFET[J].,2019,(8):1649.
[7]陈 静,陈 炜,伍 媛,等.小续命汤及其组分治疗急性脑梗死研究进展*[J].陕西中医,2019,(12):1818.
[8]王开霞,郑 超,朱晓骏,等.茵陈五苓散治疗胆汁淤积研究进展*[J].陕西中医,2019,(12):1822.
[9]贺晓立,王 军,余 静,等.沈力教授治疗乳腺癌十一法*[J].陕西中医,2020,(1):92.
　HE Xiaoli,WANG Jun,YU Jing,et al.Professor SHEN Li’s treatment of breast cancer by using eleven TCM methods[J].,2020,(8):92.
[10]王诗恒,刘剑锋△,秦培洁,等.刘剑锋教授治疗失眠临床经验[J].陕西中医,2020,(1):95.
　WANG Shiheng,LIU Jianfeng,QIN Peijie,et al.Professor Liu Jianfeng’s clinical experience in treating insomnia[J].,2020,(8):95.

备注/Memo

备注/Memo:
吉林省卫生健康科技能力提升项目（2023JC044）
更新日期/Last Update: 2026-08-13